EDC for real-world evidence studies: RWD collection, eConsent, ePRO, and 21 CFR Part 11–aligned controls for regulatory and HTA use.
21 CFR Part 11–aligned · HIPAA-aligned security · No credit card required
The regulatory landscape for real-world evidence has matured significantly. The FDA’s Real-World Evidence Program (established under the 21st Century Cures Act), the EMA’s guidances on real-world data, and similar initiatives from regulatory authorities worldwide have established clear expectations for RWE data quality. Central to these expectations is the concept of "fitness for purpose"—data must be collected and managed with quality controls appropriate for the intended regulatory use. For prospective RWE studies, fitness for purpose typically requires: a pre-specified protocol and analysis plan, informed consent documentation, structured data capture with audit trails, quality control processes (edit checks, query management), and data governance that ensures only authorized personnel can access and modify study data. These requirements closely parallel those for interventional trials, and they necessitate an EDC system with the same compliance infrastructure. Capture provides this infrastructure as standard. Every data entry is logged with timestamp, user identity, and reason for change. Electronic signatures are 21 CFR Part 11–aligned. Role-based access ensures appropriate data governance. And structured exports provide the data provenance documentation that regulatory reviewers need to assess data reliability.
Many RWE studies use hybrid designs that combine prospective data collection with retrospective data abstraction. For example, a study might retrospectively abstract baseline characteristics and treatment history from medical records while prospectively collecting outcome data, patient-reported assessments, and follow-up information. This hybrid approach leverages the efficiency of existing data while ensuring that critical endpoint data is captured with the quality controls of a prospective study. Capture supports hybrid RWE designs within a single study build. CRFs for retrospective data abstraction can be configured alongside prospective visit-based forms and ePRO assessments. The audit trail distinguishes between data entered from source documents (retrospective) and data collected in real time (prospective), providing transparency about data provenance that is essential for regulatory review. Consent workflows can accommodate the different requirements for prospective participation (active informed consent) and retrospective data use (waiver of consent or broad consent, as approved by the ethics committee).
Beyond regulatory applications, RWE is increasingly important for health technology assessment (HTA) submissions and market access strategies. HTA bodies such as NICE (UK), G-BA/IQWiG (Germany), HAS (France), and CADTH (Canada) evaluate real-world evidence as part of their assessment of clinical and cost-effectiveness. Payers use RWE to inform formulary decisions, coverage policies, and value-based agreements. For RWE to be accepted in these contexts, the data must meet standards for methodological rigor and data quality. This includes transparent data collection methods, pre-specified analysis plans, quality-controlled data capture, and documentation that supports reproducibility. An EDC system with audit trails, structured data capture, and compliant export formats provides the foundation for generating RWE that HTA bodies and payers will consider credible. Capture supports RWE programs designed for HTA and market access by providing the data governance infrastructure these stakeholders expect. Study teams can demonstrate that data was captured with appropriate quality controls, that the audit trail is complete, and that exports are reproducible—building confidence in the evidence among the diverse audience of decision-makers who will evaluate it.
Overview
Real-world evidence (RWE) studies generate evidence from real-world data (RWD) collected outside the controlled environment of traditional clinical trials. RWE is used to support regulatory decisions (label extensions, post-marketing commitments, safety evaluations), health technology assessment (HTA) submissions, payer negotiations, and clinical practice guideline development. The FDA, EMA, and other regulatory authorities have published frameworks and guidances establishing how RWE can complement traditional clinical trial data, and the use of RWE in regulatory and reimbursement decisions is growing rapidly. For RWE studies to achieve their purpose, the underlying data must be fit for purpose: captured with appropriate quality controls, traceable through audit trails, and managed with data governance standards that can withstand regulatory scrutiny. This is where many RWE programs encounter challenges. Data collected in spreadsheets, generic databases, or systems without audit trails may not meet the evidentiary standards required by regulators and HTA bodies, regardless of how well the study was designed. Your EDC must support prospective, retrospective, or hybrid data capture with consent, optional ePRO, and full auditability so data can support submissions and publications. The system should accommodate the diverse data sources common in RWE: clinician-entered CRFs, patient-reported outcomes, data abstracted from electronic health records, and patient-generated health data from wearables or mobile devices. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. The platform supports RWE study teams in collecting and managing real-world data with the data integrity and traceability that regulatory agencies and HTA bodies expect. Because all data flows into one system with one audit trail, teams can demonstrate data provenance from collection through analysis—a critical requirement for RWE that will be used in decision-making contexts.
RWE studies differ from traditional clinical trials in several ways that affect EDC requirements. Visit schedules may be driven by clinical care rather than protocol-defined windows. Data may come from multiple sources (clinician assessment, patient self-report, record abstraction) within the same study. Consent requirements may vary by jurisdiction and data source. And the evidence generated must meet standards for regulatory or HTA use that go beyond what is expected for internal analyses. Legacy EDC systems designed for interventional trials often impose structures—fixed randomization modules, mandatory treatment assignment fields, rigid visit windows—that create friction in RWE study operations. At the same time, lightweight tools (spreadsheets, REDCap, survey platforms) may lack the audit trails, electronic signatures, and access controls needed for data that will be submitted to regulatory agencies or included in HTA dossiers. The gap between what is needed and what is available is particularly acute for prospective RWE studies, where data is collected specifically to generate evidence. These studies require the same level of data governance as interventional trials—complete audit trails, signed consent records, role-based access—but with the operational flexibility to accommodate real-world care patterns. Capture is built for this use case: flexible form and visit design with 21 CFR Part 11–aligned controls and HIPAA-aligned security. The platform supports RWD collection from multiple sources within one system, with one audit trail that provides the traceability regulatory agencies require.
FAQ
Explore the platform with a free sandbox. No sales call required.